Pharmacy medication - jynarque
Ended Awarded Last action
- Contract number
- 36C26220F0487
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $235,049
Award facts
- Contract value 100% obligated
- $235,049.49 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $113,859 | |
| Original award | $121,191 |
About this award
On July 1, 2020, the Department of Veterans Affairs, specifically Veterans Integrated Service Network (VISN) 22, awarded a delivery order valued at $235,049.49 to Otsuka America Pharmaceutical Inc. for the provision of Jynarque (tolvaptan), a specialty pharmaceutical medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract, which was completed by August 12, 2021, was issued under a firm fixed-price arrangement with no set-aside designation and was performed in Pittsburgh, Pennsylvania. This delivery order was issued under the parent Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), through which Otsuka America maintains significant indefinite delivery vehicles with the VA.
Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer headquartered in Rockville, Maryland, has established itself as a primary supplier of Jynarque to the VA healthcare system. The company holds a substantial $83.3 million Blanket Purchase Agreement with the National Acquisition Center for Jynarque through March 26, 2026, enabling VA facilities across multiple Integrated Service Networks to procure this critical medication. This delivery order represents one of many task orders issued under that larger vehicle and reflects the VA's ongoing commitment to providing specialized pharmaceutical treatments to veterans with complex medical conditions across the nation.
Quick answers
Who was awarded contract 36C26220F0487?
36C26220F0487 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 22 (Veterans Health Administration) on July 1, 2020.
How much is contract 36C26220F0487 worth?
The government has obligated $235,049 on 36C26220F0487.
Is contract 36C26220F0487 an order under another contract?
Yes. 36C26220F0487 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26220F0487 competed?
The extent of competition for 36C26220F0487 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award